Pfizer: The 6.3% Yield Is A Appealing

Michael M. Santiago Pfizer (NYSE:PFE) submitted a better than expected earnings card for the fourth fiscal quarter last week. Despite a drop-off in COVID-19 related product revenues, Pfizer has been able to deliver solid organic top line growth in the fourth quarter as well as FY 2023. The pharmaceutical giant also confirmed its financial outlook and guided for Y/Y revenue upside in FY 2024. In my opinion, the drop-off in Corminaty and Paxlovid sales has created overly negative sentiment overhang for Pfizer ...